FDA flags problems with two Boston Scientific heart devices tied to injuries and deaths
Washington – American health regulators warn doctors and patients from safety problems with two Boston scientific scientific devices recently linked to injuries and deaths.
The Food and Drug Administration published two alerts on Wednesday on electrical problems linked to the company’s cardiac zapping defibrillator systems and a separate problem with a heart implant used to reduce the risk of stroke.
The agency said that the sons of Endotak Reliance of the company can become calcified, leading to failures in the supply of life rescue, according to the FDA.
The defibrillators are placed surgically in the top of the chest, where they monitor irregular heartbeat and use electric shocks to start the heart again to normal.
As of July 24, Boston Scientific reported 386 serious injuries and 16 deaths associated with this problem, the agency said.
Ten of the deaths were tried due to the device does not work properly, said the company in an email. Four were linked to attempts to surgically withdraw patients from the patients and two others were tried unrelated to the implants.
The sons of Boston Scientific were distributed between 2002 and 2021 and are no longer available, the company noted in its letter to the doctors. Some patients will have to replace the devices, although doctors should weigh the risks of the elimination procedure.
In a separate opinion, the FDA said that Boston Scientific recently updated the instructions to set up its Watchman device, which closes part of the left heart atrium to reduce the risk of stroke.
In a letter to doctors, the company noted that there is an increased risk of blockages in the blood circulation according to the level of anesthesia for patients undergoing the initial implantation procedure. Watchman is an alternative to long -term treatment with anticoagulants for increased risk patients of stroke.
As of July 30, the company reported 120 serious injuries and 17 deaths related to the issue, the FDA said.
A company survey concluded that the security problem “is not associated with the design or manufacture of any component of the Watchman system.
Cardiac devices, including defibrillators and other implants, are the largest company in Boston Scientific, representing two -thirds of its $ 5 billion in income for the last quarter.
The actions of Boston Scientific Corp. dropped by almost 1.8% on Wednesday to end $ 102.95 in negotiations.
___
The Department of Health and Sciences of the Associated Press receives the support of the Department of Science Education from Howard Hughes Medical Institute and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.
